arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

ROCKET PHARMACEUTICALS, INC.

RCKT
$3.61 ▲ +0.09 (+2.56%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
50 Visible periods
21 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

ROCKET PHARMACEUTICALS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $404.8M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -16.1%
FCF / Share $-0.41
Trailing P/E
Price / Book 1.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

50-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-47.59M
↑ +22.4%
FCF / Share Free cash flow per share
$-0.41
↑ +20.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
11
Financial Health
12
Cash Quality
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 50 quarters